Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial.

There was a marginally significant interaction for BMI category (<27, 27-30, and >30), but no interaction for sex, age (<65 or ≥65 years), region of enrollment, race, ethnicity, hemoglobin A 1c level (≤8.5% or >8.5%), duration of diabetes (<10 years or ≥10 years), history of MI, history of congestive heart failure, impaired kidney function, or baseline SGLT-2 inhibitor use.

also in 26,082 other papers